These effects are typically dose-dependent and often diminish over time with continued use
You can read the full article at Glucagon-like peptide-1 (GLP-1), an incretin hormone, has been utilized as a novel strategy for managing glucose levels in type 2 diabetes
You may not be a good fit for GLP-1 drugs if you: Have a history of pancreatitis Live with severe gastrointestinal disorders Have a personal or family history of medullary thyroid cancer or MEN 2 Are pregnant or breastfeeding Mild side effects such as nausea, digestive discomfort, or fatigue are common, especially when starting treatment
In expanded populations, comparing semaglutide versus sitagliptin for the composite outcome of myocardial infarction or stroke yielded a hazard ratio of 0.82 (95% confidence interval (CI) 0.74 to 0.91), and comparing tirzepatide versus dulaglutide for the composite outcome including mortality yielded a hazard ratio of 0.87 (95% CI 0.75 to 1.01)
Regarding approved uses, tesofensine is specifically used to treat obesity, while semaglutide is indicated for both type 2 diabetes and obesity management
